Lupin Bioresearch Center receives Zero Observations from U.S. FDA after Successful Inspection and Assessment

Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed an onsite clinical inspection from November 3 to November 6, 2025, at its Bioresearch Centre in Pune that concluded with zero 483 observations. A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations.

Nilesh Gupta, Managing Director, Lupin, said, "The successful outcome of the onsite clinical inspection and bio-analytical assessment by the U.S. FDA at our Bioresearch Centre is testament to our ongoing commitment to quality and compliance. We remain focused on improving the lives of our patients globally."

Shares of Lupin Limited was last trading in BSE at Rs. 1971.50 as compared to the previous close of Rs. 1956.05. The total number of shares traded during the day was 158642 in over 11315 trades.

The stock hit an intraday high of Rs. 2001.75 and intraday low of 1960.85. The net turnover during the day was Rs. 314420235.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals BioresearchCenter USFDA Inspection ZeroObservations